Harmony Biosciences Ebitda Over Time
| HRMY Stock | USD 34.67 1.08 3.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Harmony Biosciences Performance and Harmony Biosciences Correlation. Harmony |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. If investors know Harmony will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harmony Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.254 | Earnings Share 2.11 | Revenue Per Share 11.923 | Quarterly Revenue Growth 0.161 | Return On Assets 0.1285 |
The market value of Harmony Biosciences is measured differently than its book value, which is the value of Harmony that is recorded on the company's balance sheet. Investors also form their own opinion of Harmony Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Harmony Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harmony Biosciences' market value can be influenced by many factors that don't directly affect Harmony Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Harmony Biosciences and related stocks such as Keros Therapeutics, Janux Therapeutics, and Fennec Pharmaceuticals Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KROS | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (9.8 M) | (44.9 M) | (56.4 M) | (103.1 M) | (152.2 M) | (144.6 M) |
| JANX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (4.8 M) | (32.8 M) | (66.2 M) | (71 M) | (67.5 M) |
| FENC | (1.6 M) | (3.4 M) | (3.6 M) | (1.9 M) | (3.6 M) | (3.1 M) | (3 M) | (6.8 M) | (10.6 M) | (12.9 M) | (17.9 M) | (123 K) | (22.6 M) | (12.4 M) | (11.7 M) |
| EWTX | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (17 M) | (42.9 M) | (21.5 M) | (112.8 M) | (107.2 M) |
| PLRX | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (30.2 M) | (118 K) | (40.3 M) | (18.5 M) | (118.8 M) | (158.2 M) | (150.3 M) |
| SNDX | (12.1 M) | (12.1 M) | (12.1 M) | (6.7 M) | (23.1 M) | (20.4 M) | (43.7 M) | (61.9 M) | (75.8 M) | (57.4 M) | (71.3 M) | 26.3 M | (151.7 M) | (229.9 M) | (218.4 M) |
| RVMD | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (39.9 M) | (48.6 M) | (101.9 M) | (179.7 M) | (239.5 M) | (430.6 M) | (409.1 M) |
| VRDN | (3 M) | (3 M) | (3 M) | (297.9 K) | (6.8 M) | (11 M) | (9.5 M) | (26.1 M) | (31.8 M) | (41 M) | (109.7 M) | (78.8 M) | (128.6 M) | (234.6 M) | (222.8 M) |
| INZY | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (20.7 M) | (56.8 M) | (56 M) | (67.9 M) | (74.8 M) | (78.6 M) |
| VTYX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (7.1 M) | (67.1 M) | (108 M) | (208 M) | (197.6 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.1 M) | (77.6 M) | (149.5 M) | (142 M) |
| TVTX | (18.3 K) | (12.8 K) | (30.1 M) | (14 M) | (53 M) | (33.2 M) | (7 M) | (29.7 M) | (63.7 M) | (69.7 M) | (144 M) | (186.7 M) | (299.4 M) | (326.2 M) | (309.9 M) |
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (37.6 M) | (52.3 M) | (102.8 M) | (97.6 M) |
| REPL | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (18.9 M) | (27.8 M) | (52.6 M) | (76.5 M) | (114.4 M) | (170.3 M) | (230.2 M) | (218.7 M) |
| NVCT | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (12.9 M) | (18.9 M) | (22.9 M) | (21.8 M) |
| LYRA | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (16.5 M) | (22.1 M) | (42.6 M) | (53.9 M) | (65.2 M) | (62 M) |
| KRON | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (16.5 M) | (79.7 M) | (151.1 M) | (134.8 M) | (121.8 M) | (127.9 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (1.2 M) | (97 M) | (178.9 M) | (234 M) | (209.3 M) | (211.1 M) | (172.2 M) | (180.8 M) |
| IDYA | (14 M) | (14 M) | (14 M) | (14 M) | (14 M) | (14 M) | (14 M) | (14 M) | (35.5 M) | (43 M) | (34 M) | (48.5 M) | (60.4 M) | (130.4 M) | (123.9 M) |
| PTGX | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (14.5 M) | (27.9 M) | (37.5 M) | (41.7 M) | (77.7 M) | (63.7 M) | (123.1 M) | (128 M) | (90.3 M) | (94.9 M) |
| VRNA | (12 K) | (2.9 M) | (4.1 M) | (4.6 M) | (5.8 M) | (13.2 M) | (9.2 M) | (39.5 M) | (31.3 M) | (51.8 M) | (47.8 M) | (42.2 M) | (67.3 M) | (52.5 M) | (49.8 M) |
Harmony Biosciences and related stocks such as Keros Therapeutics, Janux Therapeutics, and Fennec Pharmaceuticals Ebitda description
My Equities
My Current Equities and Potential Positions
| Harmony Biosciences Holdings | HRMY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 34.67
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.